#PC111
Breakthrough antibody PC111 shows promise in preventing pemphigus vulgaris blistering, winning top dermatology research recognition. Innovative non-immunosuppressive treatment approach advances autoimmune disease management. #Immunotherapy #MedicalResearch
June 26, 2025 at 8:18 PM
Pioneering Treatment for Rare Skin Conditions: Scinai Webinar Highlights New Drug Development#Scinai_Immunotherapeutics#Israel#Jerusalem#Pincell#PC111
Pioneering Treatment for Rare Skin Conditions: Scinai Webinar Highlights New Drug Development
Scinai Immunotherapeutics is set to explore a groundbreaking drug for rare skin diseases in an upcoming webinar, focusing on PC111's significance.
third-news.com
May 1, 2025 at 11:33 AM
デジタル教育支援プロジェクトに使用済みPC111台が寄贈されました#デジタル教育#CLACK #ビー・エス・デーインフォメーションテクノロジー

認定NPO法人CLACKが、ビー・エス・デーインフォメーションテクノロジーより寄贈されたPCを活用し、困難を抱える中高生への支援を強化します。
デジタル教育支援プロジェクトに使用済みPC111台が寄贈されました
認定NPO法人CLACKが、ビー・エス・デーインフォメーションテクノロジーより寄贈されたPCを活用し、困難を抱える中高生への支援を強化します。
news.3rd-in.co.jp
May 28, 2025 at 6:33 AM
Scinai Immunotherapeutics hosting critical webinar on PC111 antibody for rare skin disorders, exploring groundbreaking treatment potential for Pemphigus Vulgaris and SJS/TEN #Biotech #Innovation
May 1, 2025 at 5:10 PM
Scinai to Acquire Pincell and Advance Development of Groundbreaking Monoclonal Antibody#Israel#Jerusalem#Scinai#Pincell#PC111
Scinai to Acquire Pincell and Advance Development of Groundbreaking Monoclonal Antibody
Scinai confirms its acquisition of Pincell, focusing on a novel antibody for treating severe dermatological conditions and advancing its development with a significant grant application.
third-news.com
March 27, 2025 at 1:55 PM
Scinai Immunotherapeutics receives Italian regulatory approval to acquire Pincell, strengthening its immunotherapy pipeline with promising monoclonal antibody PC111 targeting severe skin disorders #Biotech #Innovation
June 5, 2025 at 5:08 PM
Scinai Immunotherapeutics reveals breakthrough PC111 antibody with potential to transform treatment for pemphigus and severe skin conditions, offering non-immunosuppressive therapeutic approach #Biotech #Innovation
July 29, 2025 at 4:40 PM
#SCNI Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"

https://www.stocktitan.net/news/SCNI/scinai-highlights-award-winning-science-behind-pc111-as-key-pincell-5qyzz1ttb3nu.html
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"
Scinai Immunotherapeutics (NASDAQ:SCNI) announces that Dr. Roberta Lotti from Pincell Srl has received the prestigious "Oscar of Italian Dermatology" for her groundbreaking research on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. The award recognizes Dr. Lotti's paper demonstrating PC111's efficacy in treating pemphigus through a novel, non-immunosuppressive approach.PC111, which Scinai has rights to through a strategic option agreement to acquire Pincell srl, targets soluble Fas Ligand (sFasL) in Pemphigus Vulgaris (PV) and Stevens-Johnson/Toxic Epidermal Necrolysis (SJS/TEN). The research confirms that PC111 blocks blister formation by inhibiting keratinocyte apoptosis, representing a potential paradigm shift from current immunosuppressive treatments.
www.stocktitan.net
June 26, 2025 at 11:38 AM
#SCNI Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

https://www.stocktitan.net/news/SCNI/scinai-announces-new-peer-reviewed-publication-supporting-pc111-as-a-hjt0j8e8qm9r.html
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN
Scinai Immunotherapeutics (NASDAQ:SCNI) announced a new peer-reviewed publication validating PC111, their first-in-class human anti-Fas Ligand monoclonal antibody, as a potential disease-modifying therapy for pemphigus and SJS/TEN. The research, published in the Journal of Dermatological Treatment, demonstrates PC111's ability to prevent blister formation across multiple study models.The study confirms PC111's unique non-immunosuppressive mechanism, acting locally at the keratinocyte level. The treatment represents a market opportunity exceeding $1 billion annually. Scinai and Pincell plan to advance PC111 through IND-enabling studies, with potential market entry in 3-4 years. The program may receive up to 80% cost coverage through a €15 million FENG grant, pending Q3 2025 decision.
www.stocktitan.net
July 29, 2025 at 11:15 AM